$11.88
0.25% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US71722W1071
Symbol
PHAT

Phathom Pharmaceuticals Inc Target price 2025 - Analyst rating & recommendation

Phathom Pharmaceuticals Inc Classifications & Recommendation:

Buy
87%
Hold
13%

Phathom Pharmaceuticals Inc Price Target

Target Price $20.40
Price $11.88
Potential
Number of Estimates 10
10 Analysts have issued a price target Phathom Pharmaceuticals Inc 2026 . The average Phathom Pharmaceuticals Inc target price is $20.40. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 15 analysts: 13 Analysts recommend Phathom Pharmaceuticals Inc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Phathom Pharmaceuticals Inc stock has an average upside potential 2026 of . Most analysts recommend the Phathom Pharmaceuticals Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 55.25 169.91
8,025.00% 207.53%
EBITDA Margin -500.76% -99.39%
97.96% 80.15%
Net Margin -605.12% -143.50%
97.96% 76.29%

11 Analysts have issued a sales forecast Phathom Pharmaceuticals Inc 2025 . The average Phathom Pharmaceuticals Inc sales estimate is

$170m
Unlock
. This is
48.99% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$182m 59.72%
Unlock
, the lowest is
$146m 27.79%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $55.3m 8,025.00%
2025
$170m 207.53%
Unlock
2026
$334m 96.46%
Unlock
2027
$516m 54.71%
Unlock
2028
$734m 42.20%
Unlock
2029
$891m 21.27%
Unlock
2030
$1.0b 15.44%
Unlock
2031
$1.1b 11.58%
Unlock
2032
$1.2b 8.63%
Unlock

6 Analysts have issued an Phathom Pharmaceuticals Inc EBITDA forecast 2025. The average Phathom Pharmaceuticals Inc EBITDA estimate is

$-169m
Unlock
. This is
37.05% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-149m 44.30%
Unlock
, the lowest is
$-187m 30.41%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-277m 65.93%
2025
$-169m 38.96%
Unlock
2026
$41.5m 124.57%
Unlock
2027
$229m 452.86%
Unlock
2028
$428m 86.51%
Unlock
2029
$563m 31.69%
Unlock
2030
$633m 12.30%
Unlock
2031
$727m 14.93%
Unlock
2032
$760m 4.50%
Unlock

EBITDA Margin

2024 -500.76% 97.96%
2025
-99.39% 80.15%
Unlock
2026
12.43% 112.51%
Unlock
2027
44.42% 257.36%
Unlock
2028
58.27% 31.18%
Unlock
2029
63.27% 8.58%
Unlock
2030
61.56% 2.70%
Unlock
2031
63.40% 2.99%
Unlock
2032
60.99% 3.80%
Unlock

11 Phathom Pharmaceuticals Inc Analysts have issued a net profit forecast 2025. The average Phathom Pharmaceuticals Inc net profit estimate is

$-244m
Unlock
. This is
26.15% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-216m 34.68%
Unlock
, the lowest is
$-282m 14.69%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-334m 65.85%
2025
$-244m 27.07%
Unlock
2026
$-58.4m 76.04%
Unlock
2027
$93.0m 259.08%
Unlock
2028
$279m 200.01%
Unlock
2029
$372m 33.50%
Unlock
2030
$445m 19.65%
Unlock
2031
$566m 27.05%
Unlock
2032
$613m 8.27%
Unlock

Net Margin

2024 -605.12% 97.96%
2025
-143.50% 76.29%
Unlock
2026
-17.50% 87.80%
Unlock
2027
18.00% 202.86%
Unlock
2028
37.97% 110.94%
Unlock
2029
41.80% 10.09%
Unlock
2030
43.33% 3.66%
Unlock
2031
49.34% 13.87%
Unlock
2032
49.18% 0.32%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -5.29 -3.48
34.61% 34.22%
P/E negative
EV/Sales 7.46

11 Analysts have issued a Phathom Pharmaceuticals Inc forecast for earnings per share. The average Phathom Pharmaceuticals Inc EPS is

$-3.48
Unlock
. This is
23.52% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.08 32.31%
Unlock
, the lowest is
$-4.02 11.65%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-5.29 34.61%
2025
$-3.48 34.22%
Unlock
2026
$-0.83 76.15%
Unlock
2027
$1.33 260.24%
Unlock
2028
$3.98 199.25%
Unlock
2029
$5.31 33.42%
Unlock
2030
$6.35 19.59%
Unlock
2031
$8.07 27.09%
Unlock
2032
$8.74 8.30%
Unlock

P/E ratio

Current -2.61 19.87%
2025
-3.42 30.98%
Unlock
2026
-14.25 316.67%
Unlock
2027
8.96 162.88%
Unlock
2028
2.99 66.63%
Unlock
2029
2.24 25.08%
Unlock
2030
1.87 16.52%
Unlock
2031
1.47 21.39%
Unlock
2032
1.36 7.48%
Unlock

Based on analysts' sales estimates for 2025, the Phathom Pharmaceuticals Inc stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 11.11 91.78%
2025
7.46 32.89%
Unlock
2026
3.80 49.10%
Unlock
2027
2.45 35.36%
Unlock
2028
1.73 29.67%
Unlock
2029
1.42 17.54%
Unlock
2030
1.23 13.37%
Unlock
2031
1.10 10.38%
Unlock
2032
1.02 7.94%
Unlock

P/S ratio

Current 7.39 93.41%
2025
4.96 32.88%
Unlock
2026
2.52 49.10%
Unlock
2027
1.63 35.37%
Unlock
2028
1.15 29.67%
Unlock
2029
0.95 17.54%
Unlock
2030
0.82 13.37%
Unlock
2031
0.73 10.38%
Unlock
2032
0.68 7.95%
Unlock

Current Phathom Pharmaceuticals Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Craig-Hallum
Locked
Locked
Locked Jun 09 2025
HC Wainwright & Co.
Locked
Locked
Locked Jun 09 2025
Needham
Locked
Locked
Locked Jun 06 2025
Goldman Sachs
Locked
Locked
Locked May 02 2025
Guggenheim
Locked
Locked
Locked May 02 2025
HC Wainwright & Co.
Locked
Locked
Locked May 02 2025
Needham
Locked
Locked
Locked Apr 21 2025
Analyst Rating Date
Locked
Craig-Hallum:
Locked
Locked
Jun 09 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jun 09 2025
Locked
Needham:
Locked
Locked
Jun 06 2025
Locked
Goldman Sachs:
Locked
Locked
May 02 2025
Locked
Guggenheim:
Locked
Locked
May 02 2025
Locked
HC Wainwright & Co.:
Locked
Locked
May 02 2025
Locked
Needham:
Locked
Locked
Apr 21 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today